Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/29338
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | SANTOS, Tabata M. dos | - |
dc.contributor.author | RIGHETTI, Renato F. | - |
dc.contributor.author | CAMARGO, Leandro do N. | - |
dc.contributor.author | SARAIVA-ROMANHOLO, Beatriz M. | - |
dc.contributor.author | ARISTOTELES, Luciana R. C. R. B. | - |
dc.contributor.author | SOUZA, Flavia C. R. de | - |
dc.contributor.author | FUKUZAKI, Silvia | - |
dc.contributor.author | ALONSO-VALE, Maria I. C. | - |
dc.contributor.author | CRUZ, Maysa M. | - |
dc.contributor.author | PRADO, Carla M. | - |
dc.contributor.author | LEICK, Edna A. | - |
dc.contributor.author | MARTINS, Milton A. | - |
dc.contributor.author | TIBERIO, Iolanda F. L. C. | - |
dc.date.accessioned | 2018-11-21T17:00:03Z | - |
dc.date.available | 2018-11-21T17:00:03Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | FRONTIERS IN PHYSIOLOGY, v.9, article ID 1183, 19p, 2018 | - |
dc.identifier.issn | 1664-042X | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/29338 | - |
dc.description.abstract | Background: Interleukin-17 (IL-17) and Rho-kinase (ROCK) play an important role in regulating the expression of inflammatory mediators, immune cell recruitment, hyper-responsiveness, tissue remodeling, and oxidative stress. Modulation of IL-17 and ROCK proteins may represent a promising approach for the treatment of this disease. Objective: To study the effects of an anti-IL17 neutralizing antibody and ROCK inhibitor treatments, separately and in combination, in a murine model of chronic allergy-induced lung inflammation. Methods: Sixty-four BALBc mice, were divided into eight groups (n = 8): SAL (saline-instilled); OVA (exposed-ovalbumin); SAL-RHOi (saline and ROCK inhibitor), OVA-RHOi (exposed-ovalbumin and ROCK inhibitor); SAL-anti-IL17 (saline and anti-IL17); OVA-anti-IL1 7 (exposed-ovalbumin and anti-IL1 7); SAL-RHOi-anti-IL17 (saline, ROCK inhibitor and anti-IL17); and OVA-RHOi-anti-IL17 (exposed-ovalbumin, anti-IL17, and ROCK inhibitor). A 28-day protocol of albumin treatment was used for sensitization and induction of pulmonary inflammation. The anti-IL17A neutralizing antibody (7.5 mu g per treatment) was administered by intraperitoneal injection and ROCK inhibitor (Y-27632) intranasally (10 mg/kg), 1 h prior to each ovalbumin challenge (days 22, 24, 26, and 28). Results: Treatment with the anti-IL17 neutralizing antibody and ROCK inhibitor attenuated the percentage of maximal increase of respiratory system resistance and respiratory system elastance after challenge with methacholine and the inflammatory response markers evaluated (CD4(+), CD8(+), ROCK1, ROCK2, IL-4, IL-5, IL-6, IL-10 IL-13, IL-17, TNF-alpha, TGF-beta, NF-kappa B, dendritic cells, iNOS, MMP-9, MMP-12, TIMP-1, FOXP3, isoprostane, biglycan, decorin, fibronectin, collagen fibers content and gene expression of IL-17, VAChT, and arginase) compared to the OVA group (p < 0.05). Treatment with anti-IL17 and the ROCK inhibitor together resulted in potentiation in decreasing the percentage of resistance increase after challenge with methacholine, decreased the number of IL-5 positive cells in the airway, and reduced, IL-5, TGF beta, FOXP3, ROCK1 and ROCK2 positive cells in the alveolar septa compared to the OVA-RHOi and OVA-anti-IL17 groups (p < 0.05). Conclusion: Anti-IL17 treatment alone or in conjunction with the ROCK inhibitor, modulates airway responsiveness, inflammation, tissue remodeling, and oxidative stress in mice with chronic allergic lung inflammation. | - |
dc.description.sponsorship | Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/17944-1] | - |
dc.description.sponsorship | National Council of Scientific and the Technological Development (CNPq) | - |
dc.description.sponsorship | Laboratory of Medical Investigations [LIM-20 FMUSP] | - |
dc.language.iso | eng | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.relation.ispartof | Frontiers in Physiology | - |
dc.rights | openAccess | - |
dc.subject | asthma | - |
dc.subject | interleukin-17 | - |
dc.subject | Rho-kinase | - |
dc.subject | Y-27632 | - |
dc.subject | inflammation | - |
dc.subject | neutralizing antibody | - |
dc.subject.other | airway smooth-muscle | - |
dc.subject.other | allergic pulmonary inflammation | - |
dc.subject.other | tnf-alpha | - |
dc.subject.other | rheumatoid-arthritis | - |
dc.subject.other | molecular-mechanisms | - |
dc.subject.other | oxidative stress | - |
dc.subject.other | th17 cells | - |
dc.subject.other | hyperresponsiveness | - |
dc.subject.other | mice | - |
dc.subject.other | il-17a | - |
dc.title | Effect of Anti-IL17 Antibody Treatment Alone and in Combination With Rho-Kinase Inhibitor in a Murine Model of Asthma | - |
dc.type | article | - |
dc.rights.holder | Copyright FRONTIERS MEDIA SA | - |
dc.identifier.doi | 10.3389/fphys.2018.01183 | - |
dc.identifier.pmid | 30233389 | |
dc.subject.wos | Physiology | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | ALONSO-VALE, Maria I. C.:Univ Fed Sao Paulo, Dept Biol Sci, Diadema, Brazil | - |
hcfmusp.author.external | CRUZ, Maysa M.:Univ Fed Sao Paulo, Dept Biol Sci, Diadema, Brazil | - |
hcfmusp.description.articlenumber | 1183 | - |
hcfmusp.description.volume | 9 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000443766100001 | - |
hcfmusp.origem.id | 2-s2.0-85053073855 | - |
hcfmusp.publisher.city | LAUSANNE | - |
hcfmusp.publisher.country | SWITZERLAND | - |
hcfmusp.relation.reference | Adachi T, 2001, J IMMUNOL, V167, P4609, DOI 10.4049/jimmunol.167.8.4609 | - |
hcfmusp.relation.reference | Arantes-Costa FM, 2008, TOXICOL PATHOL, V36, P680, DOI 10.1177/0192623308317427 | - |
hcfmusp.relation.reference | Aristoteles LRCRB, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-52 | - |
hcfmusp.relation.reference | Banerjee S, 2016, IN VITRO CELL DEV-AN, V52, P878, DOI 10.1007/s11626-016-0050-0 | - |
hcfmusp.relation.reference | Barlow JL, 2011, CLIN EXP ALLERGY, V41, P1447, DOI 10.1111/j.1365-2222.2011.03806.x | - |
hcfmusp.relation.reference | Berry M, 2007, CURR OPIN PHARMACOL, V7, P279, DOI 10.1016/j.coph.2006.03.001 | - |
hcfmusp.relation.reference | Brown SD, 2015, J ALLERGY CLIN IMMUN, V135, P1651, DOI 10.1016/j.jaci.2014.08.054 | - |
hcfmusp.relation.reference | Brussino L, 2010, CLIN EXP ALLERGY, V40, P1642, DOI 10.1111/j.1365-2222.2010.03604.x | - |
hcfmusp.relation.reference | Camargo LD, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01835 | - |
hcfmusp.relation.reference | Chenuet P, 2017, CLIN SCI, V131, P2533, DOI 10.1042/CS20171034 | - |
hcfmusp.relation.reference | Chiba Y, 2010, J PHARMACOL SCI, V114, P239, DOI 10.1254/jphs.10R03CR | - |
hcfmusp.relation.reference | Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142 | - |
hcfmusp.relation.reference | Doe C, 2010, CHEST, V138, P1140, DOI 10.1378/chest.09-3058 | - |
hcfmusp.relation.reference | Erle DJ, 2014, J CELL BIOL, V205, P621, DOI 10.1083/jcb.201401050 | - |
hcfmusp.relation.reference | Fischer JAA, 2015, ARTHRITIS RHEUMATOL, V67, P51, DOI 10.1002/art.38896 | - |
hcfmusp.relation.reference | Goetsch KP, 2011, MATRIX BIOL, V30, P109, DOI 10.1016/j.matbio.2010.10.009 | - |
hcfmusp.relation.reference | Henry PJ, 2005, PULM PHARMACOL THER, V18, P67, DOI 10.1016/j.pupt.2004.10.002 | - |
hcfmusp.relation.reference | Kobayashi T, 2013, AM J RESP CELL MOL, V49, P989, DOI 10.1165/rcmb.2012-0444OC | - |
hcfmusp.relation.reference | Kolb M, 2001, AM J PHYSIOL-LUNG C, V280, pL1327 | - |
hcfmusp.relation.reference | Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684 | - |
hcfmusp.relation.reference | Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926 | - |
hcfmusp.relation.reference | Leffler J, 2018, IMMUNOL CELL BIOL, V96, P316, DOI 10.1111/imcb.12005 | - |
hcfmusp.relation.reference | Leick-maldonado EA, 2004, CLIN EXP ALLERGY, V34, P145, DOI 10.1111/j.1365-2222.2004.01854.x | - |
hcfmusp.relation.reference | Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V125, pS95, DOI 10.1016/j.jaci.2009.10.047 | - |
hcfmusp.relation.reference | Liang JL, 2013, J CARDIOVASC PHARM, V62, P84, DOI 10.1097/FJC.0b013e3182927ea4 | - |
hcfmusp.relation.reference | Liu Y, 2015, IMMUNOL CELL BIOL, V93, P616, DOI 10.1038/icb.2015.13 | - |
hcfmusp.relation.reference | Maarsingh H, 2008, N-S ARCH PHARMACOL, V378, P171, DOI 10.1007/s00210-008-0286-7 | - |
hcfmusp.relation.reference | Maarsingh H, 2009, BRIT J PHARMACOL, V158, P652, DOI 10.1111/j.1476-5381.2009.00374.x | - |
hcfmusp.relation.reference | Manni ML, 2016, J IMMUNOL, V196, P963, DOI 10.4049/jimmunol.1501531 | - |
hcfmusp.relation.reference | Matthey M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2288 | - |
hcfmusp.relation.reference | Meurs H, 2000, BRIT J PHARMACOL, V130, P1793, DOI 10.1038/sj.bjp.0703488 | - |
hcfmusp.relation.reference | Meyer N, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0136-8 | - |
hcfmusp.relation.reference | Mo HM, 2008, PARASITOL RES, V103, P1183, DOI 10.1007/s00436-008-1114-1 | - |
hcfmusp.relation.reference | Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929 | - |
hcfmusp.relation.reference | Mong PY, 2008, J IMMUNOL, V180, P550, DOI 10.4049/jimmunol.180.1.550 | - |
hcfmusp.relation.reference | Mrass P, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01032-2 | - |
hcfmusp.relation.reference | Nag SS, 2003, J ALLERGY CLIN IMMUN, V111, P558, DOI 10.1067/mai.2003.131 | - |
hcfmusp.relation.reference | Nastase MV, 2012, J HISTOCHEM CYTOCHEM, V60, P963, DOI 10.1369/0022155412456380 | - |
hcfmusp.relation.reference | Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550 | - |
hcfmusp.relation.reference | Newcomb DC, 2012, J IMMUNOL, V188, P1027, DOI 10.4049/jimmunol.1102216 | - |
hcfmusp.relation.reference | Pantano C, 2008, AM J RESP CRIT CARE, V177, P959, DOI 10.1164/rccm.200707-10960C | - |
hcfmusp.relation.reference | Peters M, 2016, AM J RESP CELL MOL, V54, P350, DOI 10.1165/rcmb.2014-0429OC | - |
hcfmusp.relation.reference | Pigati PA, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0073-4 | - |
hcfmusp.relation.reference | Pinheiro NM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120441 | - |
hcfmusp.relation.reference | Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4 | - |
hcfmusp.relation.reference | Possa SS, 2012, AM J PHYSIOL-LUNG C, V303, pL939, DOI 10.1152/ajplung.00034.2012 | - |
hcfmusp.relation.reference | Prado CM, 2011, EXP LUNG RES, V37, P259, DOI 10.3109/01902148.2010.538289 | - |
hcfmusp.relation.reference | Raedler D, 2015, J ALLERGY CLIN IMMUN, V135, P81, DOI 10.1016/j.jaci.2014.07.046 | - |
hcfmusp.relation.reference | Rampadarath AK, 2018, BIOPHYS J, V114, P493, DOI 10.1016/j.bpj.2017.11.020 | - |
hcfmusp.relation.reference | Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST | - |
hcfmusp.relation.reference | RighettI RF, 2014, RESP PHYSIOL NEUROBI, V192, P134, DOI 10.1016/j.resp.2013.12.012 | - |
hcfmusp.relation.reference | Rizzo CA, 2002, J ALLERGY CLIN IMMUN, V109, P404, DOI 10.1067/mai.2002.122459 | - |
hcfmusp.relation.reference | Robinson KA, 2017, MATRIX BIOL, V64, P81, DOI 10.1016/j.matbio.2017.08.004 | - |
hcfmusp.relation.reference | Sanchez-Fernandez G, 2014, CELL SIGNAL, V26, P833, DOI 10.1016/j.cellsig.2014.01.010 | - |
hcfmusp.relation.reference | Saraiva-Romanholo BM, 2003, CHEST, V124, P1060, DOI 10.1378/chest.124.3.1060 | - |
hcfmusp.relation.reference | Schaafsma D, 2004, BRIT J PHARMACOL, V143, P477, DOI 10.1038/sj.bjp.0705903 | - |
hcfmusp.relation.reference | Schaafsma D, 2008, AM J PHYSIOL-LUNG C, V295, pL214, DOI 10.1152/ajplung.00498.2007 | - |
hcfmusp.relation.reference | Schaller MA, 2005, EUR J IMMUNOL, V35, P2061, DOI 10.1002/eji.200425715 | - |
hcfmusp.relation.reference | Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401 | - |
hcfmusp.relation.reference | Shiraki A, 2009, CLIN EXP ALLERGY, V39, P236, DOI 10.1111/j.1365-2222.2008.03164.x | - |
hcfmusp.relation.reference | Song CW, 2008, J IMMUNOL, V181, P6117, DOI 10.4049/jimmunol.181.9.6117 | - |
hcfmusp.relation.reference | Taki F, 2007, CLIN EXP ALLERGY, V37, P599, DOI 10.1111/j.1365-2222.2007.02693.x | - |
hcfmusp.relation.reference | Voynow JA, 2011, BBA-GEN SUBJECTS, V1810, P1091, DOI 10.1016/j.bbagen.2011.04.016 | - |
hcfmusp.relation.reference | Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC | - |
hcfmusp.relation.reference | Wang M., 2018, CURR DRUG METAB, DOI [10.2174/1389200219666180129111810, DOI 10.2174/1389200219666180129111810] | - |
hcfmusp.relation.reference | Wang YH, 2011, CURR ALLERGY ASTHM R, V11, P388, DOI 10.1007/s11882-011-0210-y | - |
hcfmusp.relation.reference | Weibel Ewald R, 2010, Nihon Kokyuki Gakkai Zasshi, V48, P637 | - |
hcfmusp.relation.reference | Weitoft M, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-67 | - |
hcfmusp.relation.reference | Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2 | - |
hcfmusp.relation.reference | Willis CR, 2015, AM J RESP CELL MOL, V53, P810, DOI 10.1165/rcmb.2015-0038OC | - |
hcfmusp.relation.reference | Witzenrath M, 2008, EXP TOXICOL PATHOL, V60, P9, DOI 10.1016/j.etp.2008.03.002 | - |
hcfmusp.relation.reference | Wu XY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01112 | - |
hcfmusp.relation.reference | Zhang H, 2014, GENET MOL RES, V13, P8320, DOI [10.4238/2014.October.20.8, 10.4238/2014.January.22.2] | - |
hcfmusp.relation.reference | Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957 | - |
dc.description.index | PubMed | - |
hcfmusp.citation.scopus | 39 | - |
hcfmusp.scopus.lastupdate | 2024-04-18 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCM Artigos e Materiais de Revistas Científicas - FM/MPT Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - LIM/20 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_SANTOS_Effect_of_AntiIL17_Antibody_Treatment_Alone_and_in_2018.PDF | publishedVersion (English) | 4.6 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.